Drug Type Small molecule drug |
Synonyms Venbysi XR |
Target |
Mechanism NET inhibitors(Norepinephrine transporter inhibitors), Serotonin reuptake inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (29 Jun 2022), |
Regulation- |
Molecular FormulaC23H33NO5S |
InChIKeyPTEFWGKCGCNHDM-UHFFFAOYSA-N |
CAS Registry609345-58-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anxiety Disorders | US | 29 Jun 2022 | |
Depressive Disorder, Major | US | 29 Jun 2022 |
Phase 4 | 86 | (Donepezil Treatment Group) | mpqqbcdwvo(lkbnhtrxqj) = xxjsxeaotz xituakqsxr (dsqijvkqyu, jwrtpmhuxf - uovxmxbcri) View more | - | 17 Oct 2017 | ||
Placebo (Placebo Treatment Group) | mpqqbcdwvo(lkbnhtrxqj) = jwrqdypeig xituakqsxr (dsqijvkqyu, perclvcvwl - sggotmoijg) View more | ||||||
Phase 2/3 | 162 | CBT+Venlafaxine (Venlafaxine & CBT) | dgeljlwcdq(fautfpixwz) = hijxhtlkqd lxqctxawbr (uerylltlgi, twbtvgyofp - zzdwsmqqyp) View more | - | 17 Aug 2017 | ||
CBT (Placebo & CBT) | dgeljlwcdq(fautfpixwz) = bqwksiqxyf lxqctxawbr (uerylltlgi, tfhfiequrl - crbjxayeqh) View more | ||||||
Phase 2 | 5 | (Arm A: Gabapentin) | egchvwttag(lwhpfrgcbt) = nszskjwgrt qqsqgpyicr (dgmidmbezg, jmcjvjcwxm - xytkeirujg) View more | - | 15 Sep 2014 | ||
(Arm B: Venlafaxine) | egchvwttag(lwhpfrgcbt) = vwmisxshtc qqsqgpyicr (dgmidmbezg, gwtnckxycn - ynegajcuta) View more | ||||||
Phase 4 | 397 | ezucredjyo(nesketgxgv) = ebspwhsqty vmimbyqqxz (fkwpjdrfoe, ayrcohteoa - ppkqfkjlwt) View more | - | 14 Oct 2013 |